TAS 4464

Drug Profile

TAS 4464

Alternative Names: TAS-4464

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
  • Phase I Haematological malignancies; Solid tumours
  • Preclinical Endometrial cancer

Most Recent Events

  • 06 Mar 2018 Taiho Oncology terminates a phase I/II trial for Non-Hodgkin's lymphoma and Multiple myeloma (Second-line therapy or greater) in USA (IV), due to business decision (NCT02978235)
  • 09 Dec 2017 Pharmacodynamics data from preclinical studies in Mantle cell lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH 2017)
  • 31 Oct 2017 Pharmacodynamics data from a preclinical trial in Endometrial cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top